Emerging Markets Earnings Roundup: Pfizer, Lilly (Part 2)
This article was originally published in PharmAsia News
Executive Summary
Despite strong growth in emerging markets, Pfizer says multinationals are unlikely to outgrow the market rate due to competition from local companies; while Eli Lilly strives to gain more business outside the U.S.